We are monitoring the impact of COVID-19 on Asia Pacific Generic Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date August, 2019
ID: 2093
Share on
Share on

Asia Pacific Generic Drugs Market Research Report - Segmented By Type, Application, & By Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, Forecast, Growth | 2019 – 2024

Pulished: August, 2019
ID: 2093
Pages: 145

Asia Pacific Generic Drugs Market Size & Growth (2019 – 2024):

The Size of Asia Pacific Generic drugs market is valued at USD 75.62 billion in 2019 and is expected to reach USD 112.86 billion by 2024 with a CAGR of 8.34% during the forecast period 2019-2024.

Generic drugs are copies of branded drugs that have exactly the same composition, intended use, effects, side effects, risks, safety, and strength as the genuine drug. An example of a generic drug for diabetes is metformin. They are cost-effective compared to branded drugs. This market will increase tremendously during the forecast period.

Generic drugs are also known as abbreviated drugs. To sell a generic drug manufacturing company must submit an Abbreviated New Drug Application for approval. The Drug Price Competition and Patent Term Restoration Act of 1984, mostly known as the Hatch-Waxman Act, made ANDAs feasible by creating a compromise in the drug industry. Generic drug companies have obtained greater access to the market for prescription drugs and branded companies have obtained restoration of patent life for their drugs lost during the FDA's approval process.

The cost-effectiveness of abbreviated drugs has given it a competitive lead over branded drugs in the market. The key driving factor for generic drugs is patent expiry for branded drugs. Patent for Branded drugs with sales of up to USD 135 billion was expired in 2015. Nearly USD 150 billion worth of patents for branded drugs will expire by 2020 which will give generic drugs a huge advantage. 

One more trend which influences market growth is outsourcing. The presence of some key players in this market and developing economies are some driving factors in this region. Vendors are using outsourcing as a strategy to reduce their capital which will be an advantage to generic drugs. The only restraint for this market is rigid rules set up by the FDA for approval of these drugs and the threat of counterfeit drugs.

Asia Pacific Generic Drugs Market has been segmented and sub-segmented into the following categories

  • By Type: Pure Generic Drugs, Branded Generic Drugs.
  • By Application: Central Nervous System (CNS), Cardiovascular, Dermatology, Oncology, Respiratory, Others.
  • By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC

Top Companies dominating the Asia Pacific Generic Drugs Market Profiled in the Report are Ranbaxy Laboratories, Ltd, Actavis, Mylan, Inc., Industries, Ltd., Dr. Reddy’s Laboratories, Par Pharmaceutical, Inc., Sandoz International GmbH, Hospira, Inc., Apotex, Inc., Watson Pharmaceuticals, Ltd., Teva Pharmaceutical and others.

1.Introduction           

                1.1 Market Definition    

                1.2 Study Deliverables  

                1.3 Base Currency, Base Year and Forecast Periods   

                1.4 General Study Assumptions

2. Research Methodology     

                2.1 Introduction        

                2.2 Research Phases      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design  

                2.4 Study Timeline   

3. Overview 

                3.1 Executive Summary

                3.2 Key Inferences  

                3.3 Epidemology       

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)             

                4.1 Market Drivers   

                4.2 Market Restraints    

                4.3 Key Challenges  

                4.4 Current Opportunities in the Market       

5. Market Segmentation        

                5.1 Type       

                                5.1.1 Introduction           

                                5.1.2 Biosimilars               

                                5.1.3 simple generics     

                                5.1.4 Super generics      

                                5.1.5  Y-o-Y Growth Analysis, By Product              

                                5.1.6  Market Attractiveness Analysis, By Product            

                                5.1.7  Market Share Analysis, By Product              

                5.2 Therapeutic drugs   

                                5.2.1 Introduction           

                                5.2.2 Cardiovascular Products    

                                5.2.3 Anti-infective Drugs            

                                5.2.4 Anti Arthritis Drugs              

                                5.2.5 Central Nervous System Drugs       

                                5.2.6 Anti Cancer Drugs

                                5.2.7 Respiratory System Drugs

                                5.2.8 Others      

                                5.2.9 Y-o-Y Growth Analysis, By Therapeutic Drugs          

                                5.2.10 Market Attractiveness Analysis, By Therapeutic Drugs      

                                5.2.11 Market Share Analysis, By Therapeutic Drugs        

6. Geographical Analysis        

                6.1 Introduction        

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

6.1.3.1 By Geographical Area                                     

6.1.3.2 By Type                                 

6.1.3.3 By Therapeutic Drugs                                      

                                6.1.4  Market Attractiveness Analysis     

6.1.4.1 By Geographical Area                                     

6.1.4.2 By Type                                 

6.1.4.3 By Therapeutic Drugs                                      

                                6.1.5  Market Share Analysis      

6.1.5.1 By Geographical Area                                     

6.1.5.2 By type                                 

6.1.5.3 By Therapeutic Drugs                                      

              6.2 India

              6.3 China

              6.4 Japan

               6.5 Australia

                6.6 South Korea

7.Strategic Analysis  

                7.1 PESTLE analysis  

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis       

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis   

                8.1 Ranbaxy Laboratories     

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Actavis   

                8.3 Mylan, Inc. Industries, Ltd.  

                8.4 Dr. Reddy’s Laboratories      

                8.5 Par Pharmaceutical, Inc. 

                8.6 Sandoz International GmbH

                8.7 Celgene Corporation       

                8.8 Apotex, Inc.        

                8.9 Watson Pharmaceuticals, Ltd.     

                8.10 Teva Pharmaceutical and others.    

9.Competitive Landscape      

                9.1 Market share analysis     

                9.2 Merger and Acquisition Analysis

                9.3 Agreements, collaborations and Joint Ventures  

                9.4 New Product Launches  

10.Market Outlook and Investment Opportunities    

Appendix     

                a) List of Tables

                b) List of Figures       

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Generic Drugs Market By Type, From 2019-2024 ( USD Billion )
  2. Asia-Pacific Biosimilars Market By Region, From 2019-2024 ( USD Billion )
  3. Asia-Pacific Simple Generics Market By Region, From 2019-2024 ( USD Billion )
  4. Asia-Pacific Super Generics Market By Region, From 2019-2024 ( USD Billion )
  5. Asia-Pacific Generic Drugs Market By Therapeutic Drugs, From 2019-2024 ( USD Billion )
  6. Asia-Pacific Cardiovascular Drugs Market By Region, From 2019-2024 ( USD Billion )
  7. Asia-Pacific Anti-Infective Drugs Market By Region, From 2019-2024 ( USD Billion )
  8. Asia-Pacific Anti-Arthritic Drugs Market By Region, From 2019-2024 ( USD Billion )
  9. Asia-Pacific Central Nervous system Drugs Market By Region, From 2019-2024 ( USD Billion )
  10. Asia-Pacific Anti-Cancer Drugs Market By Region, From 2019-2024 ( USD Billion )
  11. Asia-Pacific Respiratory Products Market By Region, From 2019-2024 ( USD Billion )
  12. Asia-Pacific Others Market By Region, From 2019-2024 ( USD Billion )
  13. Japan Generic Drugs Market By Type, From 2019-2024 ( USD Billion )
  14. Japan Generic Drugs Market By Therapeutic Drugs, From 2019-2024 ( USD Billion )
  15. China Generic Drugs Market By Type, From 2019-2024 ( USD Billion )
  16. China Generic Drugs Market By Therapeutic Drugs, From 2019-2024 ( USD Billion )
  17. India Generic Drugs Market By Type, From 2019-2024 ( USD Billion )
  18. India Generic Drugs Market By Therapeutic Drugs, From 2019-2024 ( USD Billion )
  19. Australia Generic Drugs Market By Type, From 2019-2024 ( USD Billion )
  20. Australia Generic Drugs Market By Therapeutic Drugs, From 2019-2024 ( USD Billion )
  21. South Korea Generic Drugs Market By Type, From 2019-2024 ( USD Billion )
  22. South Korea Generic Drugs Market By Therapeutic Drugs, From 2019-2024 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample